Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing

By | 8 June 2026

Understanding the importance of ADC clinical positioning in previously treated patients against current therapies
Highlighting the updated Phase I clinical profile of IKS014 for patients with advanced HER2+ solid tumors
Addressing the concept of ADC sequencing in future treatment paradigms